These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
369 related articles for article (PubMed ID: 38259438)
1. Transmission characteristics and inactivated vaccine effectiveness against transmission of the SARS-CoV-2 Omicron BA.2 variant in Shenzhen, China. He X; Liao Y; Liang Y; Yu J; Gao W; Wan J; Liao Y; Su J; Zou X; Tang S Front Immunol; 2023; 14():1290279. PubMed ID: 38259438 [TBL] [Abstract][Full Text] [Related]
2. The effectiveness of booster vaccination of inactivated COVID-19 vaccines against susceptibility, infectiousness, and transmission of omicron BA.2 variant: a retrospective cohort study in Shenzhen, China. Liao Y; Su J; Zhao J; Qin Z; Zhang Z; Gao W; Wan J; Liao Y; Zou X; He X Front Immunol; 2024; 15():1359380. PubMed ID: 38881892 [TBL] [Abstract][Full Text] [Related]
3. Transmission Characteristics and Inactivated Vaccine Effectiveness Against Transmission of SARS-CoV-2 Omicron BA.5 Variants in Urumqi, China. Wang K; Guo Z; Zeng T; Sun S; Lu Y; Wang J; Li S; Luan Z; Li H; Zhang J; Wang Y; Lu Y; Zhao S JAMA Netw Open; 2023 Mar; 6(3):e235755. PubMed ID: 36995713 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study. He X; Zeng B; Wang Y; Pang Y; Zhang M; Hu T; Liang Y; Kang M; Tang S Front Immunol; 2023; 14():1257360. PubMed ID: 37915583 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA.5 infection: a matched cohort study of adult close contacts. Zeng T; Lu Y; Zhao Y; Guo Z; Sun S; Teng Z; Tian M; Wang J; Li S; Fan X; Wang W; Cai Y; Liao G; Liang X; He D; Wang K; Zhao S Respir Res; 2023 Oct; 24(1):246. PubMed ID: 37828565 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variants during two outbreaks from March to May 2022 in Quzhou, China. Yin Z; Fang Q; Wen T; Zheng C; Fu C; Wang S; Li J; Gong X Hum Vaccin Immunother; 2023 Dec; 19(1):2163813. PubMed ID: 36704960 [TBL] [Abstract][Full Text] [Related]
7. Inactivated SARS-CoV-2 Vaccine Booster Against Omicron Infection Among Quarantined Close Contacts. Liu D; Feng S; Sha F; Liao Y; Xie X; Huang F; Kong D; Zhang Z; Chen Z; Chen N; Gao W; Feng T; Zhao Z; Li B; Li Y; Zhu F; Yang Z; Lv Q; Feng Z; Tang J JAMA Netw Open; 2023 Oct; 6(10):e2339507. PubMed ID: 37878315 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case-control study. Zhang X; Wang Y; Hu C; Xu P; Ma L; Liu L; Sun J; Liu Y; Yang H; Pan F; Hu J; Cao C; Cheng K; Gao D; Lyu Y; Qin W Hum Vaccin Immunother; 2023 Dec; 19(1):2194189. PubMed ID: 36998173 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness against severe COVID-19 of a seasonal booster dose of bivalent (original/Omicron BA.4-5) mRNA vaccines in persons aged ≥60 years: Estimates over calendar time and by time since administration during prevalent circulation of different Omicron subvariants, Italy, 2022-2023. Fabiani M; Mateo-Urdiales A; Sacco C; Fotakis EA; Battilomo S; Petrone D; Del Manso M; Bella A; Riccardo F; Stefanelli P; Palamara AT; Pezzotti P; Vaccine; 2024 Oct; 42(23):126026. PubMed ID: 38834428 [TBL] [Abstract][Full Text] [Related]
10. Transmission risks of Omicron BA.5 following inactivated COVID-19 vaccines among children and adolescents in China. Guo Z; Zeng T; Lu Y; Sun S; Liang X; Ran J; Wu Y; Chong MKC; Wang K; Zhao S Commun Med (Lond); 2024 May; 4(1):92. PubMed ID: 38762678 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study. Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506 [TBL] [Abstract][Full Text] [Related]
12. Autoimmune Sequelae After Delta or Omicron Variant SARS-CoV-2 Infection in a Highly Vaccinated Cohort. Wee LE; Lim JT; Tay AT; Chiew CJ; Ong B; Lye DCB; Lahiri M; Tan KB JAMA Netw Open; 2024 Aug; 7(8):e2430983. PubMed ID: 39212988 [TBL] [Abstract][Full Text] [Related]
14. Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study. Moustsen-Helms IR; Bager P; Larsen TG; Møller FT; Vestergaard LS; Rasmussen M; Hansen CH; Lancet Infect Dis; 2024 Sep; 24(9):964-973. PubMed ID: 38761806 [TBL] [Abstract][Full Text] [Related]
15. How effective is the BNT162b2 mRNA vaccine against SARS-CoV-2 transmission and infection? A national programme analysis in Monaco, July 2021 to September 2022. Althaus T; Overton CE; Devaux I; House T; Lapouze A; Troel A; Vanzo B; Laroche M; Bordero A; Jorgensen P; Pebody R; Voiglio EJ BMC Med; 2024 Jun; 22(1):227. PubMed ID: 38840159 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness of BNT162b2 and Sinovac vaccines against the transmission of SARS-CoV-2 during Omicron-predominance in Hong Kong: A retrospective cohort study of COVID-19 cases. Zhao S; Guo Z; Sun S; Hung CT; Leung EYM; Wei Y; Wang H; Li K; Yam CHK; Chow TY; Gao J; Jia KM; Chong KC; Yeoh EK J Clin Virol; 2023 Sep; 166():105547. PubMed ID: 37453162 [TBL] [Abstract][Full Text] [Related]
17. Household transmission of SARS-CoV-2 during the Omicron wave in Shanghai, China: A case-ascertained study. Wei Z; Ma W; Wang Z; Li J; Fu X; Chang H; Qiu Y; Tian H; Zhu Y; Xia A; Wu Q; Liu G; Zhai X; Zhang X; Wang Y; Zeng M Influenza Other Respir Viruses; 2023 Feb; 17(2):e13097. PubMed ID: 36843225 [TBL] [Abstract][Full Text] [Related]
18. Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France. Tamandjou Tchuem CR; Auvigne V; Vaux S; Montagnat C; Paireau J; Monnier Besnard S; Gabet A; Benhajkassen N; Le Strat Y; Parent Du Chatelet I; Levy-Bruhl D Vaccine; 2023 Mar; 41(13):2280-2288. PubMed ID: 36870880 [TBL] [Abstract][Full Text] [Related]
19. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial. Lee IT; Cosgrove CA; Moore P; Bethune C; Nally R; Bula M; Kalra PA; Clark R; Dargan PI; Boffito M; Sheridan R; Moran E; Darton TC; Burns F; Saralaya D; Duncan CJA; Lillie PJ; San Francisco Ramos A; Galiza EP; Heath PT; Girard B; Parker C; Rust D; Mehta S; de Windt E; Sutherland A; Tomassini JE; Dutko FJ; Chalkias S; Deng W; Chen X; Feng J; Tracy L; Zhou H; Miller JM; Das R; Lancet Infect Dis; 2023 Sep; 23(9):1007-1019. PubMed ID: 37348519 [TBL] [Abstract][Full Text] [Related]
20. Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a retrospective matched cohort study. Mateo-Urdiales A; Sacco C; Fotakis EA; Del Manso M; Bella A; Riccardo F; Bressi M; Rota MC; Petrone D; Siddu A; Fedele G; Stefanelli P; Palamara AT; Brusaferro S; Rezza G; Pezzotti P; Fabiani M Lancet Infect Dis; 2023 Dec; 23(12):1349-1359. PubMed ID: 37478877 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]